Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome.

Detailed Description
-----------------
Restless Legs Syndrome (RLS) is a very common neurological disorder with a prevalence of approximately 10% in the adult population. It is characterized by an almost irresistible urge to move the legs, usually accompanied by feelings of intense discomfort. The feelings are usually present while at rest and are temporarily relieved by activity. Symptoms are worse in the evening and at night and lead to profound sleep disturbance and daytime fatigue. Although a number of therapeutic approaches have been used to treat the symptoms of RLS, none have been universally adopted. While it has been shown that some dopaminergic anti-parkinsonian medications are effective in treating RLS, their use may be somewhat limited by side effects associated with long-term dopaminergic activation. Istradefylline may provide a nondopaminergic approach to the treatment of RLS. This study will compare the efficacy of 40 mg per day of istradefylline in improving the symptoms of RLS with placebo.

Official Title
-----------------
A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) in Subjects With Restless Legs Syndrome

Conditions
-----------------
Sleep Disorder, Restless Legs Syndrome

Intervention / Treatment
-----------------
* Drug: Istradefylline (KW-6002)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RLS that is mild to moderate in severity, non-nursing and non-pregnant if female, with an otherwise normal examination. Exclusion Criteria: Unable to stop other RLS medication, treatment with excluded medications, abnormal medical status.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Istradefylline (KW-6002)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in an RLS rating scale score at endpoint (6 weeks of treatment or early discontinuation). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline values in an RLS rating scale score, in the a sleepiness scale, in values for Clinical Global Impression, in quality of life, and in actigraphic measurements. |  |  | 
| Safety |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep -Sleep Disorder, Sleep- Restless Legs Syndrome, Clinical Trial